ArticleInternational journal of molecular sciences2019
MicroRNA-137 Inhibits Cancer Progression by Targeting Del-1 in Triple-Negative Breast Cancer Cells.
Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- EDIL3/Del-1-Dependent Induction of AMPKβ Phosphorylation Regulates the Progression of Mesenchymal Stem-like Triple-Negative Breast Cancer.International journal of molecular sciences · 2026Article
- Article
- A feedback loop between lncRNA MALAT1 and DNMT1 promotes triple-negative breast cancer stemness and tumorigenesis.Cancer biology & therapy · 2023Article
- Multidimensional computational study to understand non-coding RNA interactions in breast cancer metastasis.Scientific reports · 2023Article
- Convolutional neural network for biomarker discovery for triple negative breast cancer with RNA sequencing data.Heliyon · 2023Article
- Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy.International journal of molecular sciences · 2023Review
- MicroRNAs: A Link between Mammary Gland Development and Breast Cancer.International journal of molecular sciences · 2022Review
- Response to neoadjuvant chemotherapy in breast cancer: do microRNAs matter?Discover oncology · 2022Article
- miR-3614-3p suppresses cell aggressiveness of human breast cancer by targetingTranslational cancer research · 2022Article
- Prognostic Value of miR-137 in Children with Medulloblastoma and its Regulatory Effect on Tumor Progression.Neuromolecular medicine · 2022Article
- Article
- miR-497 inhibits proliferation and invasion in triple-negative breast cancer cells via YAP1.Oncology letters · 2021Article
- miR‑335 promotes ferroptosis by targeting ferritin heavy chain 1 inInternational journal of molecular medicine · 2021Article
- LncRNA HAS2-AS1 Promotes Glioblastoma Proliferation by Sponging miR-137.Frontiers in oncology · 2021Article
- CircWHSC1 Promotes Breast Cancer Progression by Regulating the FASN/AMPK/mTOR Axis Through Sponging miR-195-5p.Frontiers in oncology · 2021Article
- microRNA-1298 inhibits the malignant behaviors of breast cancer cells via targeting ADAM9.Bioscience reports · 2020Article
- Long Non-Coding RNA NCK1-AS1 Serves an Oncogenic Role in Gastric Cancer by Regulating miR-137/NUP43 Axis.OncoTargets and therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
MicroRNAs (miRNAs) can be used to target a variety of human malignancy by targeting their oncogenes or tumor suppressor genes. The developmental endothelial locus-1 (Del-1) might be under miRNA regulation. This study investigated microRNA-137 (miR-137) function and Del-1 expression in triple-negative breast cancer (TNBC) cells and tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.